Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 145

1.

Estimation of the cost of treatment by chemotherapy for early breast cancer in Morocco.

Boutayeb S, Boutayeb A, Ahbeddou N, Boutayeb W, Ismail E, Tazi M, Errihani H.

Cost Eff Resour Alloc. 2010 Sep 10;8:16. doi: 10.1186/1478-7547-8-16.

2.

First data on direct costs of lung cancer management in Morocco.

Tachfouti N, Belkacemi Y, Raherison C, Bekkali R, Benider A, Nejjari C.

Asian Pac J Cancer Prev. 2012;13(4):1547-51.

3.

Direct costs of cervical cancer management in Morocco.

Berraho M, Najdi A, Mathoulin-Pelissier S, Salamon R, Nejjari C.

Asian Pac J Cancer Prev. 2012;13(7):3159-63.

4.

Repaglinide : a pharmacoeconomic review of its use in type 2 diabetes mellitus.

Plosker GL, Figgitt DP.

Pharmacoeconomics. 2004;22(6):389-411. Review.

PMID:
15099124
5.

A systematic overview of chemotherapy effects in breast cancer.

Bergh J, Jönsson PE, Glimelius B, Nygren P; SBU-group. Swedish Council of Technology Assessment in Health Care..

Acta Oncol. 2001;40(2-3):253-81. Review.

PMID:
11441936
6.

Information technology facilitates cost-effectiveness analysis in developing countries: an observational study of breast cancer chemotherapy in Taiwan.

Shih YC, Pan IW, Tsai YW.

Pharmacoeconomics. 2009;27(11):947-61. doi: 10.2165/11314110-000000000-00000.

PMID:
19888794
8.

Is adjuvant therapy for older patients with node (+) early breast cancer cost-effective?

Naeim A, Keeler EB.

Breast Cancer Res Treat. 2005 Nov;94(2):95-103.

PMID:
16261407
10.
11.

Breast cancer management: quality-of-life and cost considerations.

Radice D, Redaelli A.

Pharmacoeconomics. 2003;21(6):383-96. Review.

PMID:
12678566
12.
13.

The curability of breast cancer and the treatment of advanced disease.

Guarneri V, Conte PF.

Eur J Nucl Med Mol Imaging. 2004 Jun;31 Suppl 1:S149-61. Review.

PMID:
15107948
14.

Adjuvant therapy for breast cancer.

[No authors listed]

NIH Consens Statement. 2000 Nov 1-3;17(4):1-35. Review.

PMID:
11512506
15.

Economic evaluation of the prevention and treatment of breast cancer--present status and open issues.

Imai H, Kuroi K, Ohsumi S, Ono M, Shimozuma K.

Breast Cancer. 2007;14(1):81-7. Review.

16.

Concurrent chemoradiotherapy in adjuvant treatment of breast cancer.

Ismaili N, Mellas N, Masbah O, Elmajjaoui S, Arifi S, Bekkouch I, Ahid S, Bazid Z, Tazi MA, Erraki A, El Mesbahi O, Benjaafar N, El Gueddari Bel K, Ismaili M, Afqir S, Errihani H.

Radiat Oncol. 2009 Apr 7;4:12. doi: 10.1186/1748-717X-4-12.

17.

Letrozole: a pharmacoeconomic review of its use in postmenopausal women with breast cancer.

Dunn C, Keam SJ.

Pharmacoeconomics. 2006;24(5):495-517. Review.

PMID:
16706574
18.

Metastatic breast cancer with liver metastases: a registry analysis of clinicopathologic, management and outcome characteristics of 500 women.

Pentheroudakis G, Fountzilas G, Bafaloukos D, Koutsoukou V, Pectasides D, Skarlos D, Samantas E, Kalofonos HP, Gogas H, Pavlidis N.

Breast Cancer Res Treat. 2006 Jun;97(3):237-44.

PMID:
16322882
19.

Cost of depression in Europe.

Sobocki P, Jönsson B, Angst J, Rehnberg C.

J Ment Health Policy Econ. 2006 Jun;9(2):87-98.

PMID:
17007486
20.

[Current trends in pharmacotherapy of breast cancer].

Boér K.

Orv Hetil. 2002 Apr 7;143(14):725-30. Review. Hungarian.

PMID:
11975393
Items per page

Supplemental Content

Support Center